By Professor Murray David Norris

Book Chapters

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2021, 'Cell-based methods for the identification of Myc-inhibitory small molecules', in The Myc Gene: Methods and Protocols, pp. 337 - 346, http://dx.doi.org/10.1007/978-1-0716-1476-1_19

Fletcher J; Roundhill E; Haber M; Norris M, 2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52

Norris MD; Burkhart CA; Haber M; Gudkov AV; Nikiforov MA, 2013, 'Cell-Based Methods for the Identification of MYC-Inhibitory Small Molecules', in Soucek L; Sodir NM (ed.), The Myc Gene, Humana Press Inc, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18

Cheung L; Murray JE; Norris MD; Haber M, 2013, 'Oncogene and Cancer - From Bench to Clinic', in Siregar YE; norris (ed.), Oncogene and Cancer - From Bench to Clinic, Inst za onkologiju i radiol, pp. 437 - 454, http://dx.doi.org/10.5772/54813

Xue C; Gudkov A; Haber M; Norris MD, 2012, 'Small molecule drugs and targeted therapies for neuroblastoma', in Shimada H (ed.), Neuroblastoma - Present and Future, In Tech, Croatia, pp. 299 - 324, http://www.amazon.com/Neuroblastoma-Present-and-Future-ebook/dp/B00CBWQI92/ref=sr_1_1?ie=UTF8&qid=1366940364&sr=8-1&keywords=neuroblastoma+-+present+and+future#reader_B00CBWQI92

Fletcher JI; Haber M; Henderson M; Norris MD, 2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2012, 'The Myc Gene: Methods and Protocols: Myc inhibitory molecules', in Methods in Molecular Biology, Humana Press

Cheung NC; Norris MD, 2000, 'Detection of Microscopic Residual Tumors in Bone Marrow', in Neuroblastoma, Elsevier Science BV, Amsterdam, pp. 333 - 340

Journal articles

Hanssen KM; Murray J; Pandher R; Alfred S; Gamble LD; Brand J; Mosmann E; Kusuma FK; Mak C; Kearns A; Kamili A; Atkinson C; Minchaca AZ; Bertoldo J; Ziegler DS; Mussai F; Cheng PNM; Norris MD; Fletcher JI; Haber M, 2025, 'Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03502-8

Atkinson C; Kamili A; Tactacan CM; Jayatilleke N; Rosser SPA; Saletta F; Gana CC; Graber P; Wanninayaka A; Ignacio RMC; Kavallaris M; Gifford AJ; Lock RB; Norris MD; Haber M; Mayoh C; Nath CE; Trahair TN; Fletcher JI, 2025, 'P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma', Ejc Paediatric Oncology, 6, http://dx.doi.org/10.1016/j.ejcped.2025.100478

Han JZR; Phimmachanh M; Hastings JF; Leong KH; Ng BH; Ni J; Fontaine-Titley A; Cadell AL; O'Donnell YE; Clearwater M; Kamili A; Haber M; Norris M; Timpson P; Trahair TN; Fletcher JI; Fey D; Kolch W; Latham SL; Croucher DR, 2025, 'Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma', Science Advances, 11, pp. eady5599, http://dx.doi.org/10.1126/sciadv.ady5599

Murray J; Somers K; Mak C; Alfred S; Brand J; Poon E; Fletcher N; Li P; Thurecht K; Gray J; Pearson AD; Chesler L; Hogarty MD; Giles F; Fletcher J; Ziegler DS; Norris MD; Haber M, 2025, 'The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model', MOLECULAR CANCER THERAPEUTICS, 24, pp. B79 - B79, http://dx.doi.org/10.1158/1535-7163.TARG-25-B079

Pandher R; Xue C; Gamble LD; Milazzo G; Giacomo SD; Murray J; Cheung L; Ferrucci F; Palombo M; Purgato S; Burkhart CA; Fedtsova N; Gleiberman AS; Purmal AA; Korotchkina L; Nikiforov MA; Makarov SS; Telfer TJ; Codd R; Marshall GM; Scott DA; Osterman AL; Gudkov AV; Perini G; Haber M; Norris MD, 2025, 'The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response', Proceedings of the National Academy of Sciences of the United States of America, 122, http://dx.doi.org/10.1073/pnas.2420011122

Azfar M; Gao W; Van den Haute C; Xiao L; Karsa M; Pandher R; Karsa A; Spurling D; Ronca E; Bongers A; Guo X; Mayoh C; Fayt Y; Schoofs A; Burns MR; Verhelst SHL; Norris MD; Haber M; Vangheluwe P; Somers K, 2025, 'The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma', Molecular Oncology, 19, pp. 913 - 936, http://dx.doi.org/10.1002/1878-0261.13789

Gao W; Karsa M; Xiao L; Spurling D; Karsa A; Ronca E; Bongers A; Guo X; Mayoh C; Azfar M; Verhelst SHL; Tanaka K; Cheung LC; Kotecha RS; Lock RB; Burns MR; Vangheluwe P; Norris MD; Haber M; Somers K, 2025, 'Polyamine depletion limits progression of acute leukaemia', International Journal of Cancer, 156, pp. 2360 - 2376, http://dx.doi.org/10.1002/ijc.35362

Porter G; Norris MD; Apte M; Merlot AM, 2025, 'Spatial profiling of endoplasmic reticulum stress markers in tumor associated cells predicts patient outcomes in pancreatic cancer', Neoplasia United States, 60, http://dx.doi.org/10.1016/j.neo.2024.101115

Cheung BB; Mittra R; Murray J; Wang Q; Seneviratne JA; Raipuria M; Wong IPL; Restuccia D; Gifford A; Salib A; Sutton S; Huang L; Ferdowsi PV; Tsang J; Sekyere E; Mayoh C; Luo L; Brown DL; Stow JL; Zhu S; Young RJ; Solomon BJ; Chappaz S; Kile B; Kueh A; Herold MJ; Hilton DJ; Liu T; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM, 2024, 'Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis', Communications Biology, 7, pp. 1322, http://dx.doi.org/10.1038/s42003-024-06899-8

Murray JE; Valli E; Milazzo G; Mayoh C; Gifford AJ; Fletcher JI; Xue C; Jayatilleke N; Salehzadeh F; Gamble LD; Rouaen JRC; Carter DR; Forgham H; Sekyere EO; Keating J; Eden G; Allan S; Alfred S; Kusuma FK; Clark A; Webber H; Russell AJ; de Weck A; Kile BT; Santulli M; De Rosa P; Fleuren EDG; Gao W; Wilkinson-White L; Low JKK; Mackay JP; Marshall GM; Hilton DJ; Giorgi FM; Koster J; Perini G; Haber M; Norris MD, 2024, 'The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-49871-0

Seneviratne JA; Ravindrarajah D; Carter DR; Zhai V; Lalwani A; Krishan S; Balachandran A; Ng E; Pandher R; Wong M; Nero TL; Wang S; Norris MD; Haber M; Liu T; Parker MW; Cheung BB; Marshall GM, 2024, 'Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma', Cancer Medicine, 13, pp. e70082, http://dx.doi.org/10.1002/cam4.70082

Hassan N; Yi H; Malik B; Gaspard-Boulinc L; Samaraweera SE; Casolari DA; Seneviratne J; Balachandran A; Chew T; Duly A; Carter DR; Cheung BB; Norris M; Haber M; Kavallaris M; Marshall GM; Zhang XD; Liu T; Wang J; Liebermann DA; D'Andrea RJ; Wang JY, 2024, 'Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML', Blood, 144, pp. 84 - 98, http://dx.doi.org/10.1182/blood.2024024072

Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K, 2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4

Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A, 2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2

Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR, 2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M; Moles Meler E, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Hastings JF; Latham SL; Kamili A; Wheatley MS; Han JZR; Wong-Erasmus M; Phimmachanh M; Nobis M; Pantarelli C; Cadell AL; O’Donnell YEI; Leong KH; Lynn S; Geng FS; Cui L; Yan S; Achinger-Kawecka J; Stirzaker C; Norris MD; Haber M; Trahair TN; Speleman F; De Preter K; Cowley MJ; Bogdanovic O; Timpson P; Cox TR; Kolch W; Fletcher JI; Fey D; Croucher DR, 2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314

Murray J; Pandher R; Xiao L; Somers K; Brand J; Mosmann E; Alfred S; Kusuma F; Keams A; Park JR; Marshall LV; Gorrini C; Chesler L; Hogarty MD; Pearson ADJ; Burns M; Fletcher JI; Ziegler D; Norris MD; Haber M, 2023, 'Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', MOLECULAR CANCER THERAPEUTICS, 22, http://dx.doi.org/10.1158/1535-7163.TARG-23-B132

Novototskaya-Vlasova KA; Neznanov NS; Molodtsov I; Hall BM; Commane M; Gleiberman AS; Murray J; Haber M; Norris MD; Leonova KI; Gudkov AV, 2022, 'Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors', Proceedings of the National Academy of Sciences of the United States of America, 119, http://dx.doi.org/10.1073/pnas.2213146119

Hanssen KM; Wheatley MS; Yu DMT; Conseil G; Norris MD; Haber M; Cole SPC; Fletcher JI, 2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, 289, pp. 3854 - 3875, http://dx.doi.org/10.1111/febs.16374

Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K, 2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329

Lau LMS; Mayoh C; Xie J; Barahona P; MacKenzie KL; Wong M; Kamili A; Tsoli M; Failes TW; Kumar A; Mould EVA; Gifford A; Chow SO; Pinese M; Fletcher JI; Arndt GM; Khuong-Quang DA; Wadham C; Batey D; Eden G; Trebilcock P; Joshi S; Alfred S; Gopalakrishnan A; Khan A; Grebert Wade D; Strong PA; Manouvrier E; Morgan LT; Span M; Lim JY; Cadiz R; Ung C; Thomas DM; Tucker KM; Warby M; McCowage GB; Dalla-Pozza L; Byrne JA; Saletta F; Fellowes A; Fox SB; Norris MD; Tyrrell V; Trahair TN; Lock RB; Cowley MJ; Ekert PG; Haber M; Ziegler DS; Marshall GM; Trahair T, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608

Gao J; Jung M; Williams RT; Hui D; Russell AJ; Naim AJ; Kamili A; Clifton M; Bongers A; Mayoh C; Ho G; Scott CL; Jessup W; Haber M; Norris MD; Henderson MJ, 2022, 'Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer', Cancers, 14, pp. 1878, http://dx.doi.org/10.3390/cancers14081878

Karsa M; Ronca E; Bongers A; Mariana A; Moles E; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Kavallaris M; Haber M; Norris MD; Henderson MJ; Xiao L; Somers K; Moles Meler E, 2022, 'Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia', Frontiers in Oncology, 11, pp. 779859, http://dx.doi.org/10.3389/fonc.2021.779859

Seneviratne JA; Carter DR; Mittra R; Gifford A; Kim PY; Luo JS; Mayoh C; Salib A; Rahmanto AS; Murray J; Cheng NC; Nagy Z; Wang Q; Kleynhans A; Tan O; Sutton SK; Xue C; Chung SA; Zhang Y; Sun C; Zhang L; Haber M; Norris MD; Fletcher JI; Liu T; Dilda PJ; Hogg PJ; Cheung BB; Marshall GM, 2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349

Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R, 2022, 'Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions', British Journal of Cancer, 127, pp. 908 - 915, http://dx.doi.org/10.1038/s41416-022-01806-6

Khan A; Gamble LD; Upton DH; Ung C; Yu DMT; Ehteda A; Pandher R; Mayoh C; Hébert S; Jabado N; Kleinman CL; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS, 2021, 'Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas', Nature Communications, 12, pp. 971, http://dx.doi.org/10.1038/s41467-021-20896-z

Gifford AJ; Murray J; Fletcher JI; Marshall GM; Norris MD; Haber M, 2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310

Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB, 2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8

Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O’Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M, 2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357

Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K, 2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x

Xiao L; Yeung H; Haber M; Norris MD; Somers K, 2021, 'Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors', Trends in Cancer, 7, pp. 751 - 777, http://dx.doi.org/10.1016/j.trecan.2021.05.002

Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG', Cell Reports, 35, pp. 108994, http://dx.doi.org/10.1016/j.celrep.2021.108994

Gamble LD; Purgato S; Henderson MJ; Di Giacomo S; Russell AJ; Pigini P; Murray J; Valli E; Milazzo G; Giorgi FM; Cowley M; Ashton LJ; Bhalshankar J; Schleiermacher G; Rihani A; Van Maerken T; Vandesompele J; Speleman F; Versteeg R; Koster J; Eggert A; Noguera R; Stallings RL; Tonini GP; Fong K; Vaksman Z; Diskin SJ; Maris JM; London WB; Marshall GM; Ziegler DS; Hogarty MD; Perini G; Norris MD; Haber M, 2021, 'A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma', Cancers, 13, pp. 1807, http://dx.doi.org/10.3390/cancers13081807

Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM, 2021, 'A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma', Oncogene, 40, pp. 2367 - 2381, http://dx.doi.org/10.1038/s41388-021-01712-w

Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY, 2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN; Vijayasubhash V, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, 126, pp. 482 - 491, http://dx.doi.org/10.1038/s41416-021-01538-z

Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB, 2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; Di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris MD; Haber M; Milazzo G; Perini G, 2020, 'Corrigendum to: “MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma” [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235–245] (BBA - Gene Regulatory Mechanisms (2018) 1861(3) (235–245), (S1874939917302894), (10.1016/j.bbagrm.2018.01.007))', Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1863, http://dx.doi.org/10.1016/j.bbagrm.2020.194645

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ; OBrien T; Wong-Erasmus M, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ, 2020, 'ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer', International Journal of Cancer, 147, pp. 2225 - 2238, http://dx.doi.org/10.1002/ijc.33005

Back to profile page